title: Opposing effects of DNA hypomethylation on intestinal and liver carcinogenesis.
abstract: Genome-wide DNA hypomethylation and concomitant promoter-specific tumor suppressor gene hypermethylation are among the most common molecular alterations in human neoplasia. Consistent with the notion that both promoter hypermethylation and genome-wide hypomethylation are functionally important in tumorigenesis, genetic and/or pharmacologic reduction of DNA methylation levels results in suppression or promotion of tumor incidence, respectively, depending on the tumor cell type. For instance, DNA hypomethylation promotes tumors that rely predominantly on loss of heterozygosity (LOH) or chromosomal instability mechanisms, whereas loss of DNA methylation suppresses tumors that rely on epigenetic silencing. Mutational and epigenetic silencing events in Wnt pathway genes have been identified in human colon tumors. We used Apc(Min/+) mice to investigate the effect of hypomethylation on intestinal and liver tumor formation. Intestinal carcinogenesis in Apc(Min/+) mice occurs in two stages, with the formation of microadenomas leading to the development of macroscopic polyps. Using Dnmt1 hypomorphic alleles to reduce genomic methylation, we observed elevated incidence of microadenomas that were associated with LOH at Apc. In contrast, the incidence and growth of macroscopic intestinal tumors in the same animals was strongly suppressed. In contrast to the overall inhibition of intestinal tumorigenesis in hypomethylated Apc(Min/+) mice, hypomethylation caused development of multifocal liver tumors accompanied by Apc LOH. These findings support the notion of a dual role for DNA hypomethylation in suppressing later stages of intestinal tumorigenesis, but promoting early lesions in the colon and liver through an LOH mechanism.
authors.affiliation: Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology, Nine Cambridge Center, Cambridge, MA 02142, USA.
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Yamada
authors.forename: Laurie
authors.initials: L
authors.lastname: Jackson-Grusby
authors.forename: Heinz
authors.initials: H
authors.lastname: Linhart
authors.forename: Alex
authors.initials: A
authors.lastname: Meissner
authors.forename: Amir
authors.initials: A
authors.lastname: Eden
authors.forename: Haijiang
authors.initials: H
authors.lastname: Lin
authors.forename: Rudolf
authors.initials: R
authors.lastname: Jaenisch
mesh_terms: D000236:Adenoma / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D000818:Animals; D043171:Chromosomal Instability / Q000235:genetics; D019175:DNA Methylation; D044127:Epigenesis, Genetic / Q000235:genetics; D020868:Gene Silencing; D016678:Genome; D006801:Humans; D007414:Intestinal Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D008113:Liver Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D019656:Loss of Heterozygosity / Q000235:genetics; D051379:Mice; D008817:Mice, Mutant Strains; D011127:Polyps / Q000235:genetics* / Q000378:metabolism / Q000473:pathology